

Khalid Iqbal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6066539/publications.pdf>

Version: 2024-02-01

186
papers

23,814
citations

6250

80
h-index

7944

149
g-index

192
all docs

192
docs citations

192
times ranked

19283
citing authors

#	ARTICLE	IF	CITATIONS
1	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
2	Tau in Alzheimer Disease and Related Tauopathies. <i>Current Alzheimer Research</i> , 2010, 7, 656-664.	0.7	822
3	Tau pathology in Alzheimer disease and other tauopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 198-210.	1.8	786
4	Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. <i>Nature Medicine</i> , 1996, 2, 783-787.	15.2	768
5	Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. <i>European Journal of Neuroscience</i> , 2005, 22, 1942-1950.	1.2	657
6	O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10804-10809.	3.3	650
7	Tau and neurodegenerative disease: the story so far. <i>Nature Reviews Neurology</i> , 2016, 12, 15-27.	4.9	603
8	Mechanisms of tau-induced neurodegeneration. <i>Acta Neuropathologica</i> , 2009, 118, 53-69.	3.9	577
9	Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain. <i>Journal of Neurochemistry</i> , 1993, 61, 921-927.	2.1	489
10	Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. <i>European Journal of Neuroscience</i> , 2007, 25, 59-68.	1.2	461
11	DEFECTIVE BRAIN MICROTUBULE ASSEMBLY IN ALZHEIMER'S DISEASE. <i>Lancet</i> , The, 1986, 328, 421-426.	6.3	450
12	Distribution of Active Glycogen Synthase Kinase 3 β (GSK-3 β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 1010-1019.	0.9	429
13	Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. <i>Neuroscience Letters</i> , 1986, 65, 351-355.	1.0	413
14	Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. <i>Journal of Pathology</i> , 2011, 225, 54-62.	2.1	401
15	Phosphatase Activity Toward Abnormally Phosphorylated τ : Decrease in Alzheimer Disease Brain. <i>Journal of Neurochemistry</i> , 1995, 65, 732-738.	2.1	398
16	Phosphorylation of Microtubule-associated Protein Tau Is Regulated by Protein Phosphatase 2A in Mammalian Brain. <i>Journal of Biological Chemistry</i> , 2000, 275, 5535-5544.	1.6	374
17	Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. <i>Brain</i> , 2009, 132, 1820-1832.	3.7	350
18	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344

#	ARTICLE	IF	CITATIONS
19	Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S123-S139.	1.2	318
20	Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 70-78.	0.9	316
21	Glycosylation of microtubule-associated protein tau: An abnormal posttranslational modification in Alzheimer's disease. <i>Nature Medicine</i> , 1996, 2, 871-875.	15.2	310
22	Brain Levels of Microtubule-Associated Protein ? Are Elevated in Alzheimer's Disease: A Radioimmuno-Slot-Blot Assay for Nanograms of the Protein. <i>Journal of Neurochemistry</i> , 1992, 59, 750-753.	2.1	298
23	Up-Regulation of Phosphorylated/Activated p70 S6 Kinase and Its Relationship to Neurofibrillary Pathology in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2003, 163, 591-607.	1.9	294
24	Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations. <i>Journal of Biological Chemistry</i> , 2004, 279, 34873-34881.	1.6	251
25	Dephosphorylation of Alzheimer Paired Helical Filaments by Protein Phosphatase-2A and $\hat{2}B$. <i>Journal of Biological Chemistry</i> , 1995, 270, 4854-4860.	1.6	238
26	A Non-transgenic Mouse Model (icv-STZ Mouse) of Alzheimer's Disease: Similarities to and Differences from the Transgenic Model (3xTg-AD Mouse). <i>Molecular Neurobiology</i> , 2013, 47, 711-725.	1.9	226
27	Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. <i>Brain Research</i> , 1998, 797, 267-277.	1.1	220
28	Failure of Neuronal Maturation in Alzheimer Disease Dentate Gyrus. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 78-84.	0.9	212
29	Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. <i>FASEB Journal</i> , 2008, 22, 3224-3233.	0.2	210
30	Up-Regulation of Inhibitors of Protein Phosphatase-2A in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2005, 166, 1761-1771.	1.9	203
31	Alzheimer's disease, a multifactorial disorder seeking multitherapies. <i>Alzheimer's and Dementia</i> , 2010, 6, 420-424.	0.4	186
32	Phosphorylation of Tau at Thr212, Thr231, and Ser262 Combined Causes Neurodegeneration. <i>Journal of Biological Chemistry</i> , 2010, 285, 30851-30860.	1.6	177
33	τ , is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. <i>FEBS Letters</i> , 1998, 436, 28-34.	1.3	174
34	Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3 $\hat{2}$. <i>FEBS Letters</i> , 2002, 530, 209-214.	1.3	174
35	Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 8864-8869.	3.3	174
36	Tau Becomes a More Favorable Substrate for GSK-3 When It Is Prephosphorylated by PKA in Rat Brain. <i>Journal of Biological Chemistry</i> , 2004, 279, 50078-50088.	1.6	168

#	ARTICLE	IF	CITATIONS
37	Brain glucose transporters, <i>GlucNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. Journal of Neurochemistry</i> , 2009, 111, 242-249.	2.1	167
38	Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. <i>FEBS Letters</i> , 2000, 485, 87-93.	1.3	165
39	Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 41-48.	1.2	156
40	Restoration of biological activity of Alzheimer abnormally phosphorylated τ , by dephosphorylation with protein phosphatase-2A, τ 2B and τ 1. <i>Molecular Brain Research</i> , 1996, 38, 200-208.	2.5	152
41	Tau passive immunization inhibits not only tau but also $A\beta$ pathology. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 1.	3.0	147
42	Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. <i>FEBS Letters</i> , 1994, 351, 80-84.	1.3	146
43	Potential of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. <i>Molecular and Cellular Biochemistry</i> , 1997, 167, 99-105.	1.4	144
44	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. <i>Annals of Neurology</i> , 2005, 58, 748-757.	2.8	144
45	PP2A Regulates Tau Phosphorylation Directly and also Indirectly via Activating GSK-3 β . <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1221-1229.	1.2	143
46	Alzheimer paired helical filaments Restoration of the biological activity by dephosphorylation. <i>FEBS Letters</i> , 1994, 349, 104-108.	1.3	142
47	Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. <i>Acta Neuropathologica</i> , 2007, 113, 501-511.	3.9	140
48	Alzheimer's Disease Abnormally Phosphorylated τ , Is Dephosphorylated by Protein Phosphatase-2B (Calcineurin). <i>Journal of Neurochemistry</i> , 2002, 62, 803-806.	2.1	137
49	Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome. <i>Journal of Biological Chemistry</i> , 2008, 283, 28660-28669.	1.6	136
50	Okadaic-Acid-Induced Inhibition of Protein Phosphatase 2A Produces Activation of Mitogen-Activated Protein Kinases ERK1/2, MEK1/2, and p70 S6, Similar to That in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2003, 163, 845-858.	1.9	134
51	Interaction of Tau Isoforms with Alzheimer's Disease Abnormally Hyperphosphorylated Tau and in Vitro Phosphorylation into the Disease-like Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 37967-37973.	1.6	131
52	Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. <i>FEBS Letters</i> , 2004, 566, 261-269.	1.3	131
53	Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. <i>FEBS Letters</i> , 2002, 512, 101-106.	1.3	123
54	Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. <i>Neurobiology of Aging</i> , 2007, 28, 1148-1162.	1.5	123

#	ARTICLE	IF	CITATIONS
55	Downregulation of cAMP-dependent protein kinase by overactivated calpain in Alzheimer disease brain. <i>Journal of Neurochemistry</i> , 2007, 103, 2462-2470.	2.1	123
56	Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 1-12.	1.2	120
57	Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments. <i>Molecular Brain Research</i> , 1988, 4, 43-52.	2.5	119
58	Protein changes in senile dementia. <i>Brain Research</i> , 1974, 77, 337-343.	1.1	118
59	Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. <i>FEBS Letters</i> , 2001, 507, 81-87.	1.3	116
60	PKA modulates GSK-3 β - and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. <i>FEBS Letters</i> , 2006, 580, 6269-6274.	1.3	114
61	Hyperphosphorylation determines both the spread and the morphology of tau pathology. <i>Alzheimer's and Dementia</i> , 2016, 12, 1066-1077.	0.4	112
62	Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S107-S117.	1.2	112
63	The regulation of phosphorylation of τ , in SY5Y neuroblastoma cells: the role of protein phosphatases. <i>FEBS Letters</i> , 1998, 426, 248-254.	1.3	108
64	The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. <i>Acta Neuropathologica</i> , 2003, 105, 225-232.	3.9	108
65	Involvement of in the abnormal hyperphosphorylation of tau and its reversal by Memantine. <i>FEBS Letters</i> , 2006, 580, 3973-3979.	1.3	106
66	Dynamic Regulation of Expression and Phosphorylation of Tau by Fibroblast Growth Factor-2 In Neural Progenitor Cells from Adult Rat Hippocampus. <i>Journal of Neuroscience</i> , 1999, 19, 5245-5254.	1.7	102
67	Anesthesia Induces Phosphorylation of Tau. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 619-626.	1.2	101
68	Activation of Asparaginyl Endopeptidase Leads to Tau Hyperphosphorylation in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2013, 288, 17495-17507.	1.6	100
69	Cross talk between PI3K-AKT-GSK-3 β and PP2A pathways determines tau hyperphosphorylation. <i>Neurobiology of Aging</i> , 2015, 36, 188-200.	1.5	99
70	Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles. <i>Biochemical Pharmacology</i> , 2014, 88, 631-639.	2.0	95
71	Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by $\text{PP2A}^{\text{C}}/\text{SET}$. <i>FEBS Letters</i> , 2011, 585, 2653-2659.	1.3	94
72	Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces A β level and microglia activation in the brains of 3xTg-AD mice. <i>Experimental Neurology</i> , 2014, 261, 610-619.	2.0	94

#	ARTICLE	IF	CITATIONS
73	Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting A β and tau pathologies in 3xTg-AD mice. <i>Acta Neuropathologica</i> , 2010, 120, 605-621.	3.9	93
74	Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. <i>FEBS Letters</i> , 1994, 341, 94-98.	1.3	92
75	Role of tau phosphorylation by glycogen synthase kinase-3 β in the regulation of organelle transport. <i>Journal of Cell Science</i> , 2004, 117, 1653-1663.	1.2	92
76	Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. <i>Acta Neuropathologica</i> , 2005, 109, 25-31.	3.9	89
77	Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. <i>FEBS Letters</i> , 1995, 358, 4-8.	1.3	87
78	Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. <i>FEBS Letters</i> , 2001, 490, 15-22.	1.3	87
79	Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 27.	1.7	86
80	Intracerebroventricular Streptozotocin Exacerbates Alzheimer-Like Changes of 3xTg-AD Mice. <i>Molecular Neurobiology</i> , 2014, 49, 547-562.	1.9	85
81	Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 34.	1.7	85
82	Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. <i>Nucleic Acids Research</i> , 2011, 39, 6161-6171.	6.5	84
83	Isolation of neurons and glial cells from normal and pathological human brains. <i>Brain Research</i> , 1972, 45, 296-301.	1.1	82
84	Targeting Tau Protein in Alzheimer's Disease. <i>Drugs and Aging</i> , 2010, 27, 351-365.	1.3	82
85	Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 50.	4.4	82
86	Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion. <i>Journal of Biological Chemistry</i> , 2012, 287, 30497-30506.	1.6	81
87	Hyperphosphorylation-Induced Tau Oligomers. <i>Frontiers in Neurology</i> , 2013, 4, 112.	1.1	80
88	The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. <i>FASEB Journal</i> , 2010, 24, 4420-4432.	0.2	79
89	Tau pathology involves protein phosphatase 2A in Parkinsonism-dementia of Guam. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1144-1149.	3.3	79
90	Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. <i>Journal of Neural Transmission</i> , 2015, 122, 607-617.	1.4	79

#	ARTICLE	IF	CITATIONS
91	O-GlcNAcylation: A regulator of tau pathology and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2016, 12, 1078-1089.	0.4	79
92	Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. <i>FEBS Letters</i> , 1995, 358, 267-272.	1.3	77
93	Cytosolic Abnormally Hyperphosphorylated Tau But Not Paired Helical Filaments Sequester Normal MAPs and Inhibit Microtubule Assembly. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 365-370.	1.2	76
94	Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. <i>Neurobiology of Aging</i> , 2011, 32, 1420-1434.	1.5	76
95	Cyclic AMP-dependent Protein Kinase Regulates the Alternative Splicing of Tau Exon 10. <i>Journal of Biological Chemistry</i> , 2011, 286, 14639-14648.	1.6	76
96	Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation. <i>PLoS ONE</i> , 2012, 7, e35277.	1.1	76
97	Regulation of phosphorylation of neuronal microtubule-associated proteins MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain. <i>Brain Research</i> , 2000, 853, 299-309.	1.1	75
98	Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/A β Antibody and by mGluR5 Blockade. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 71.	1.7	75
99	Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease. <i>Journal of Neurochemistry</i> , 1989, 52, 1523-1528.	2.1	73
100	Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3xTg-AD mice. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 13.	3.0	73
101	Phosphorylation of τ Protein by Casein Kinase II Converts It to an Abnormal Alzheimer-Like State. <i>Journal of Neurochemistry</i> , 1995, 64, 1420-1423.	2.1	72
102	Inhibitors of protein phosphatase-2A from human brain structures, immunocytochemical localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. <i>FEBS Letters</i> , 2005, 579, 363-372.	1.3	72
103	Regulation between O-GlcNAcylation and phosphorylation of neurofilament M and their dysregulation in Alzheimer disease. <i>FASEB Journal</i> , 2008, 22, 138-145.	0.2	72
104	An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. <i>Acta Neuropathologica</i> , 2012, 123, 133-151.	3.9	72
105	Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2014, 71, 110-130.	2.1	71
106	Blood-Cerebrospinal Fluid Barrier Permeability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 505-515.	1.2	70
107	Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. <i>FEBS Letters</i> , 1996, 387, 145-148.	1.3	69
108	PP2A 1 Affects Tau Phosphorylation via Association with the Catalytic Subunit of Protein Phosphatase 2A. <i>Journal of Biological Chemistry</i> , 2008, 283, 10513-10521.	1.6	68

#	ARTICLE	IF	CITATIONS
109	Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. <i>Journal of Neurochemistry</i> , 2004, 88, 298-310.	2.1	66
110	Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 307-318.	1.5	65
111	Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. <i>FEBS Letters</i> , 1998, 436, 471-475.	1.3	61
112	Cytoplasmic Retention of Protein Phosphatase 2A Inhibitor 2 (I2PP2A) Induces Alzheimer-like Abnormal Hyperphosphorylation of Tau. <i>Journal of Biological Chemistry</i> , 2014, 289, 27677-27691.	1.6	59
113	Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. <i>Biochemical Society Transactions</i> , 2010, 38, 962-966.	1.6	58
114	Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. <i>FEBS Letters</i> , 2006, 580, 5925-5933.	1.3	56
115	Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer's Disease: A Therapeutic Target. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-11.	3.0	56
116	Comparison of the phosphorylation of microtubule-associated protein tau by non-proline dependent protein kinases. <i>Molecular and Cellular Biochemistry</i> , 1994, 131, 181-189.	1.4	55
117	Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. <i>Neuroscience Letters</i> , 2003, 340, 107-110.	1.0	54
118	Neurogenic and Neurotrophic Effects of BDNF Peptides in Mouse Hippocampal Primary Neuronal Cell Cultures. <i>PLoS ONE</i> , 2013, 8, e53596.	1.1	54
119	Truncation of Tau selectively facilitates its pathological activities. <i>Journal of Biological Chemistry</i> , 2020, 295, 13812-13828.	1.6	54
120	Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. <i>Journal of Neural Transmission</i> , 2015, 122, 593-606.	1.4	53
121	Beneficial Effect of a CNTF Tetrapeptide on Adult Hippocampal Neurogenesis, Neuronal Plasticity, and Spatial Memory in Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1185-1195.	1.2	51
122	Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I. <i>Journal of Biological Chemistry</i> , 2015, 290, 15219-15237.	1.6	51
123	Cerebrospinal Fluid Secretory Ca ²⁺ -Dependent Phospholipase A2 Activity Is Increased in Alzheimer Disease. <i>Clinical Chemistry</i> , 2009, 55, 2171-2179.	1.5	48
124	Opportunities and challenges in developing Alzheimer disease therapeutics. <i>Acta Neuropathologica</i> , 2011, 122, 543-549.	3.9	47
125	Brain Gene Expression of a Sporadic (icv-STZ Mouse) and a Familial Mouse Model (3xTg-AD Mouse) of Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e51432.	1.1	47
126	Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2701-2712.	1.5	46

#	ARTICLE	IF	CITATIONS
127	Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. <i>Neurobiology of Aging</i> , 2014, 35, 2134-2146.	1.5	45
128	Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. <i>FEBS Letters</i> , 2010, 584, 3359-3365.	1.3	44
129	Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated τ , by neuroleptics. <i>Brain Research</i> , 1996, 741, 95-102.	1.1	43
130	Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 100.	1.7	41
131	Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 311.	1.7	40
132	Decrease of Protein Phosphatase 2A and its Association with Accumulation and Hyperphosphorylation of Tau in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 295-302.	1.2	39
133	Regulation of Phosphorylation of tau by Protein Kinases in Rat Brain. <i>Neurochemical Research</i> , 2006, 31, 1473-1480.	1.6	37
134	Recent developments with tau-based drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 399-410.	2.5	35
135	Alzheimer's disease brain contains tau fractions with differential prion-like activities. <i>Acta Neuropathologica Communications</i> , 2021, 9, 28.	2.4	35
136	A Novel Therapeutic Approach to Treat Alzheimer's Disease by Neurotrophic Support During the Period of Synaptic Compensation. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1211-1218.	1.2	33
137	Mechanism of Tau Hyperphosphorylation Involving Lysosomal Enzyme Asparagine Endopeptidase in a Mouse Model of Brain Ischemia. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 821-833.	1.2	33
138	Cerebrospinal fluid secretory Ca ²⁺ -dependent phospholipase A2 activity: A biomarker of blood-cerebrospinal fluid barrier permeability. <i>Neuroscience Letters</i> , 2010, 478, 179-183.	1.0	30
139	Pathological Alterations of Tau in Alzheimer's Disease and 3xTg-AD Mouse Brains. <i>Molecular Neurobiology</i> , 2019, 56, 6168-6183.	1.9	29
140	Rescue of Synaptic Failure and Alleviation of Learning and Memory Impairments in a Trisomic Mouse Model of Down Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 1070-1079.	0.9	28
141	O-GlcNAc cycling modulates neurodegeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17319-17320.	3.3	27
142	Animal Models of the Sporadic Form of Alzheimer's Disease: Focus on the Disease and Not Just the Lesions. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 469-474.	1.2	27
143	Young blood plasma reduces Alzheimer's disease-like brain pathologies and ameliorates cognitive impairment in 3xTg-AD mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 70.	3.0	27
144	Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection. <i>Acta Neuropathologica</i> , 2014, 127, 243-256.	3.9	26

#	ARTICLE	IF	CITATIONS
145	Enhancement of Neurogenesis and Memory by a Neurotrophic Peptide in Mild to Moderate Traumatic Brain Injury. <i>Neurosurgery</i> , 2015, 76, 201-215.	0.6	26
146	Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 837649.	1.7	26
147	A pool of β -tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain. <i>FEBS Letters</i> , 2001, 509, 375-381.	1.3	25
148	Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 45.	3.0	25
149	GSK-3 β is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 365-375.	1.2	24
150	Guanosine Triphosphate Binding to β -Subunit of Tubulin in Alzheimer's Disease Brain: Role of Microtubule-Associated Protein 1. <i>Journal of Neurochemistry</i> , 2002, 64, 777-787.	2.1	23
151	Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. <i>Scientific Reports</i> , 2017, 7, 45561.	1.6	23
152	Inhibitors of protein phosphatase-2A: topography and subcellular localization. <i>Molecular Brain Research</i> , 2004, 126, 146-156.	2.5	21
153	Synaptic Compensation as a Probable Cause of Prolonged Mild Cognitive Impairment in Alzheimer's Disease: Implications from a Transgenic Mouse Model of the Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1385-1401.	1.2	21
154	Involvement of Activation of Asparaginyl Endopeptidase in Tau Hyperphosphorylation in Repetitive Mild Traumatic Brain Injury. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 709-722.	1.2	20
155	Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. <i>PLoS ONE</i> , 2015, 10, e0145441.	1.1	20
156	Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in β APP Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 743-752.	1.2	19
157	Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 423-435.	1.2	19
158	Sera from Children with Autism Induce Autistic Features Which Can Be Rescued with a CNTF Small Peptide Mimetic in Rats. <i>PLoS ONE</i> , 2015, 10, e0118627.	1.1	18
159	Prevention of Amyloid- β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 215-230.	1.2	18
160	Role of Ciliary Neurotrophic Factor in the Proliferation and Differentiation of Neural Stem Cells. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 587-592.	1.2	17
161	Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer's disease and related neurodegenerative conditions. <i>Neural Regeneration Research</i> , 2014, 9, 1518.	1.6	17
162	Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases. <i>Neurochemical Research</i> , 2000, 25, 107-120.	1.6	15

#	ARTICLE	IF	CITATIONS
163	Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 557-564.	1.2	15
164	Neonatal Exposure to Anesthesia Leads to Cognitive Deficits in Old Age: Prevention with Intranasal Administration of Insulin in Mice. <i>Neurotoxicity Research</i> , 2020, 38, 299-311.	1.3	15
165	Multiple forms of phosphatase from human brain: isolation and partial characterization of affinity blue nonbinding phosphatase activities. <i>Neurochemical Research</i> , 2001, 26, 425-438.	1.6	12
166	Inhibition of AMD-Like Pathology With a Neurotrophic Compound in Aged Rats and 3xTg-AD Mice. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 309.	1.7	10
167	Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 631-646.	1.2	10
168	Stratification of Patients is the Way to Go to Develop Neuroprotective/Disease-Modifying Drugs for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 339-345.	1.2	9
169	Elevation of casein kinase 1 μ associated with TDP43 and tau pathologies in Alzheimer's disease. <i>Brain Pathology</i> , 2020, 30, 283-297.	2.1	9
170	Subacute to chronic Alzheimer-like alterations after controlled cortical impact in human tau transgenic mice. <i>Scientific Reports</i> , 2019, 9, 3789.	1.6	8
171	Alzheimer's disease research in Ibero America. <i>Alzheimer's and Dementia</i> , 2016, 12, 749-754.	0.4	7
172	Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 102.	3.0	7
173	Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 273-286.	1.2	5
174	Seeding-Competent Tau in Gray Matter Versus White Matter of Alzheimer's Disease Brain. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1647-1659.	1.2	4
175	Thinking beyond the Aducanumab Controversy. <i>Annals of Neurology</i> , 2021, 90, 1003-1004.	2.8	4
176	Heightened Tameness and Accelerated Handling-Habituation in 3xTg-AD Mice on a B6;129 Genetic Background. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 245-255.	1.2	4
177	O2-06-04: A NOVEL PHARMACOLOGIC THERAPEUTIC APPROACH TO ALZHEIMER DISEASE AND COGNITIVE AGING. , 2014, 10, P175-P175.		1
178	Rats Display Sexual Dimorphism in Phosphorylation of Brain Tau with Age. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 855-869.	1.2	1
179	Does proteopathic tau propagate trans-synaptically in the brain?. <i>Molecular Neurodegeneration</i> , 2022, 17, 21.	4.4	1
180	O3-04-05: Rescue of pathology and cognitive impairment by tau immunotherapy at a moderate to severe stage of the disease in 3xTg-alzheimer's disease mice. , 2015, 11, P227-P227.		0

#	ARTICLE	IF	CITATIONS
181	O4-04-03: Molecular Mechanism of Tau Spread and Tau Sites to Target for Immunotherapy. , 2016, 12, P340-P341.		0
182	[F3â€™07â€™02]: TAU IMMUNOTHERAPY PREVENTS THE SPREAD AND PROMOTES THE CLEARANCE OF PATHOLOGY IN MICE. Alzheimer's and Dementia, 2017, 13, P888.	0.4	0
183	[P2â€™169]: ALZHEIMER'S DISEASE IN DOWN SYNDROME CAN BE PREVENTED BY PHARMACOLOGIC TREATMENT DURING PRENATAL TO EARLY POSTNATAL DEVELOPMENT. Alzheimer's and Dementia, 2017, 13, P671.	0.4	0
184	P3â€™055: RESCUE OF NEUROTROPHIC DEFICIT DURING PRENATAL TO EARLY POSTNATAL DEVELOPMENT CAN PREVENT ALZHEIMERâ€™LIKE COGNITIVE IMPAIRMENT LATER IN LIFE. Alzheimer's and Dementia, 2018, 14, P1085.	0.4	0
185	Why delay in effective treatment for Alzheimer's disease and related conditions. Progress in Molecular Biology and Translational Science, 2019, 168, 243-256.	0.9	0
186	Tau immunotherapy rescues cognitive impairment by clearing extracellular tau. Alzheimer's and Dementia, 2020, 16, e037315.	0.4	0